Healthcare / Medical DevicesNasdaqCM
$0.77
+0.05 (+6.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-22.7M · quality 61.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
8/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$17M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-202.3%
↓Gross Margin
N/A
•Debt/Equity
1.75
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-25.1M · FCF $-19.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | — | — | — | $300000.00 | $189000.00 | $270000.00 |
| Net Income | $-25.1M | $-25.1M | — | $-38.1M | $-23.7M | $-19.9M |
| EBITDA | $-21.2M | $-21.2M | — | $-36.0M | $-23.0M | $-19.6M |
| EPS | — | — | — | -2.85 | -1.77 | -1.49 |
| Gross Margin | — | — | — | -335.3% | -363.0% | -328.9% |
| Operating Margin | — | — | — | -9314.0% | -12652.4% | -7646.3% |
| Net Margin | — | — | — | -12715.3% | -12525.4% | -7384.4% |
| Balance Sheet | ||||||
| Debt/Equity | 1.75 | 1.75 | 0.82 | -0.29 | -0.10 | — |
| Current Ratio | 1.85 | 1.85 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-19.4M | $-19.4M | — | $-26.0M | $-22.9M | $-20.6M |
| Returns | ||||||
| ROE | -202.3% | -202.3% | — | 28.9% | 24.7% | — |
| Valuation | ||||||
| P/B | 1.38 | 1.38 | 0.85 | — | — | — |
| Growth & Yield | ||||||
| Revenue Growth | — | — | — | 58.7% | -30.0% | — |
| EPS Growth | — | — | — | -61.1% | -18.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-31.9%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → n/d
Residual
-31.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.